Kiyoshi Yamaguchi

Kiyoshi Yamaguchi

Auto-generated profile, based on publicly available information

Kiyoshi Yamaguchi

Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2022 in Nature
Verified
Journal Article
Closed access
PDF file
TWTeh-Wei Wang
Teh-Wei Wang
YJYoshikazu Johmura
Yoshikazu Johmura
NSNarumi Suzuki
Narumi Suzuki
SOSatotaka Omori
Satotaka Omori
TMToshiro Migita
Toshiro Migita
MNMakoto Nakanishi
Makoto Nakanishi

15 January 2021 in Science
Verified
Journal Article
Closed access
PDF file
YJYoshikazu Johmura
Yoshikazu Johmura
TYTakehiro Yamanaka
Takehiro Yamanaka
SOSatotaka Omori
Satotaka Omori
TWTeh-Wei Wang
Teh-Wei Wang
Yuki SugiuraYuki Sugiura
Yuki Sugiura
MNMakoto Nakanishi
Makoto Nakanishi
Selective destruction of senescent cells: Senescent cells are associated with a variety of age-related medical conditions and thus have been proposed as potential targets for therapy, but we do not yet have a full understanding of the underlying mechanisms. Johmura et al. used RNA interference to screen for enzymes essential to the survival of senescent cells (see the Perspective by Pan and Locasale). The authors identified a key role for glutamine metabolism, particularly the enzyme glutaminase 1, and demonstrated that inhibition of this pathway induced the death of senescent cells. Glutaminase targeting also ameliorated aging-related organ dysfunction and obesity-related disorders in mouse models, suggesting the potential therapeutic value of this approach. Science , this issue p. 265 ; see also p. 234

28 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ECErica Carolina
Erica Carolina
YKYoshiki Kuse
Yoshiki Kuse
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
TTTomomi Tadokoro
Tomomi Tadokoro
HTHideki Taniguchi
Hideki Taniguchi
In fetal development, tissue interaction such as the interplay between blood vessel (BV) and epithelial tissue is crucial for organogenesis. Here we recapitulate the spatial arrangement between liver epithelial tissue and the portal vein to observe the formation of intrahepatic bile ducts (BDs) from human induced pluripotent stem cells (hiPSC). We co-culture hiPSC-liver progenitors on the artificial BV consisting of immature smooth muscle cells and endothelial cells, both derived from hiPSCs. After 3 weeks, liver progenitors within hiPSC-BV-incorporated liver organoids (BVLO) differentiate to cholangiocytes and acquire epithelial characteristics, including intercellular junctions, microvilli on the apical membrane, and secretory functions. Furthermore, liver surface transplanted-BVLO temporarily attenuates cholestatic injury symptoms. Single cell RNA sequence analysis suggests that BD interact with the BV in BVLO through TGFβ and Notch pathways. Knocking out JAG1 in hiPSC-BV significantly attenuates bile duct formation, highlighting BVLO potential as a model for Alagille syndrome, a congenital biliary disease. Overall, we develop a novel 3D co-culture method that successfully establishes functional human BDs by emulating liver epithelial-BV interaction.

22 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
YJYoshikazu Johmura
Yoshikazu Johmura
IMIchiro Maeda
Ichiro Maeda
NSNarumi Suzuki
Narumi Suzuki
WWWenwen Wu
Wenwen Wu
AGAtsushi Goda
Atsushi Goda
MNMakoto Nakanishi
Makoto Nakanishi
The agonistic/antagonistic biocharacter of selective estrogen receptor modulators (SERMs) can have therapeutic advantages, particularly in the case of premenopausal breast cancers. Although the contradictory effects of these modulators have been studied in terms of crosstalk between the estrogen receptor α (ER) and coactivator dynamics and growth factor signaling, the molecular basis of these mechanisms is still obscure. We identify a series of regulatory mechanisms controlling cofactor dynamics on ER and SERM function, whose activities require F-box protein 22 (Fbxo22). Skp1, Cullin1, F-box-containing complex (SCFFbxo22) ubiquitylated lysine demethylase 4B (KDM4B) complexed with tamoxifen-bound (TAM-bound) ER, whose degradation released steroid receptor coactivator (SRC) from ER. Depletion of Fbxo22 resulted in ER-dependent transcriptional activation via transactivation function 1 (AF1) function, even in the presence of SERMs. In living cells, TAM released SRC and KDM4B from ER in a Fbxo22-dependent manner. SRC release by TAM required Fbxo22 on almost all ER-SRC-bound enhancers and promoters. TAM failed to prevent the growth of Fbxo22-depleted, ER-positive breast cancers both in vitro and in vivo. Clinically, a low level of Fbxo22 in tumor tissues predicted a poorer outcome in ER-positive/human epidermal growth factor receptor type 2-negative (HER2-negative) breast cancers with high hazard ratios, independently of other markers such as Ki-67 and node status. We propose that the level of Fbxo22 in tumor tissues defines a new subclass of ER-positive breast cancers for which SCFFbxo22-mediated KDM4B degradation in patients can be a therapeutic target for the next generation of SERMs.

19 September 2024 in Biomaterials
Verified
Journal Article
Open access
STShunsuke Tabe
Shunsuke Tabe
KTKenta Takeuchi
Kenta Takeuchi
KAKenji Aoshima
Kenji Aoshima
AOAyumu Okumura
Ayumu Okumura
YYYuya Yamamoto
Yuya Yamamoto
HTHideki Taniguchi
Hideki Taniguchi
Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with a poor prognosis. It contains a complex tumor microenvironment (TME) that includes various stromal cell types. Comprehending cellular communications within the TME is difficult due to a lack of research models that can recapitulate human PDAC-TME. Previously, we recapitulated, in part, the PDAC-TME containing a diversity of cancer-associated fibroblasts (CAFs) in vitro. This was done by establishing a PDAC organoid by co-culturing patient-derived cancer cells with human induced pluripotent stem cell (hiPSC)-derived mesenchymal and endothelial cells, which was designated the fused pancreatic cancer organoid (FPCO). We further incorporated macrophages derived from the THP-1 cell line, which are the source of tumor-associated macrophages (TAMs), a major TME component, into FPCO, which was designated M0-FPCO. Bulk RNA sequencing (RNAseq) analysis revealed that macrophages in M0-FPCO (FPCO-Mac) lost their pro-inflammatory features but acquired pro-angiogenic features. Consistently, the formation of an endothelial cell network was enhanced in M0-FPCO. Single-cell RNA-seq (scRNA-seq) analysis revealed that M0-FPCO contained five TAM subpopulations similar to the corresponding TAM in human PDAC tissue in the integrated analysis, including SPP1+-TAM, which has been correlated with tumor angiogenesis and cell proliferation. Focusing on PDAC cells, we found that they could survive longer within the organoid in the presence of TAM. Consistent with the prolonged proliferation and survival of PDAC cells, PDAC subclusters were characterized by proliferative features, such as increased M0-FPCO. Therefore, by establishing a PDAC organoid with macrophages, we recapitulated the diversity of TAMs and identified the role of TAM in endothelial network formation as well as in the modulation of PDAC cell properties. SIGNIFICANCE: PDAC organoids, including macrophages using hiPSC, showed that PDAC-TAM has angiogenic features and contributes to PDAC cell survival.

10 July 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
TOTomoyuki Ohsugi
Tomoyuki Ohsugi
KYKiyoshi Yamaguchi
Kiyoshi Yamaguchi
CZChi Zhu
Chi Zhu
TITsuneo Ikenoue
Tsuneo Ikenoue
KTKiyoko Takane
Kiyoko Takane
YFYoichi Furukawa
Yoichi Furukawa